The Department of Drug Administration (DDA) has revoked the production permits for 47 types of medicines in Nepal, issuing a notice after the deadline set in an earlier notice related to risk assessment expired. The affected medicines are made by companies that produce drugs used to treat various diseases and to control immunity.
Permits cancelled after risk-assessment deadline
The department said the permits were cancelled after the deadline in its earlier notice passed. The action therefore follows a risk-assessment process initiated through that notice. The DDA’s latest notice formally records the cancellation of production authorization for the 47 medicine types.
The decision concerns medicines made by companies operating in Nepal’s pharmaceutical sector. The products span drugs used for different diseases as well as medicines associated with controlling immunity. The information provided in the notice, as reported by Nagarik News, does not identify the medicines or manufacturers in the details available here.
What the notice establishes
The department’s action is specifically described as a revocation of production permits. It establishes that the affected products no longer hold the production authorization covered by the notice. The reported information does not provide further details about the individual medicines, the companies involved, or the basis of the risk assessments for each product.
Nor does the information provided specify whether the decision includes instructions concerning medicines already manufactured or distributed. Those details should not be assumed from the permit cancellation alone. The notice’s stated sequence is that an earlier risk-assessment notice set a deadline, that deadline expired, and the department then revoked the permits for 47 types of medicines.
The DDA is the government body named in the notice as responsible for the action. Its decision affects production permissions for medicines used across several treatment and immunity-control categories, rather than being described as a cancellation of permits for only one disease or one type of medicine.
The revocation marks the outcome of the department’s notice-and-deadline process. Further information about the products and manufacturers would be needed to determine the specific scope of the affected list or any related measures beyond the cancellation of production permits.
